Literature DB >> 18248970

Oesophagectomy after definitive chemoradiation in patients with locally advanced oesophageal cancer.

S Borghesi1, M A Hawkins, D Tait.   

Abstract

AIMS: The clinical benefit of salvage oesophagectomy in patients who recur after radical chemoradiotherapy (CRT) is not clearly defined. This study retrospectively evaluated the outcome in patients who underwent salvage oesophagectomy having failed primary CRT.
MATERIALS AND METHODS: Between March 1999 and October 2005, 181 patients with oesophageal cancer were treated at the Royal Marsden Hospital with definitive CRT. Ten patients underwent salvage oesophagectomy. All of them had locally advanced cancer of the oesophagus at presentation (adenocarcinoma in three patients and squamous cell carcinoma in seven patients) and received combined CRT, consisting of 12 weeks of cisplatin and 5-fluorouracil-based chemotherapy followed by CRT. Radiotherapy was delivered with a computed tomography-planned technique to a dose of 54 Gy with daily 5-fluorouracil.
RESULTS: An Ivor-Lewis procedure was carried out in all cases. The median time between the end of CRT and surgery was 5 months (range 1-67). Curative resection was achieved in three patients, seven had microscopic positive circumferential margins. One patient died postoperatively and complications occurred in four cases: anastomotic leak in two patients, pneumonia in one patient, empyema and sepsis in one patient. The median critical care unit stay was 7 days (range 4-26) and hospitalisation was 21 days (range 15-84). With a median follow-up period of 45.5 months (range 5-89) the 1-, 2- and 3-year survival calculated from the completion of CRT was 70, 50 and 30%, respectively. Median survival was 21.5 months (range 8-90).
CONCLUSIONS: Salvage oesophagectomy may prolong survival in carefully selected patients with local relapse. Patients fit for surgery at presentation benefit from a more intensive follow-up protocol to detect early recurrence.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18248970     DOI: 10.1016/j.clon.2007.12.001

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  15 in total

Review 1.  Perioperative management of esophageal cancer.

Authors:  Alicia Okines; Bhupinder Sharma; David Cunningham
Journal:  Nat Rev Clin Oncol       Date:  2010-03-09       Impact factor: 66.675

Review 2.  Optimal therapeutic strategies for resectable oesophageal or oesophagogastric junction cancer.

Authors:  Branislav Bystricky; Alicia F C Okines; David Cunningham
Journal:  Drugs       Date:  2011-03-26       Impact factor: 9.546

Review 3.  Oesophageal cancer--an overview.

Authors:  Michael Schweigert; Attila Dubecz; Hubert J Stein
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-01-08       Impact factor: 46.802

4.  [Salvage surgery in esophageal cancer : Feasibility in patients after definitive radiochemotherapy (> 50 Gy)].

Authors:  T Schmidt; L Sisic; F Sterzing; G-M Haag; R Kunzmann; L Grenacher; W Weichert; D Jäger; M W Büchler; K Ott
Journal:  Chirurg       Date:  2015-10       Impact factor: 0.955

Review 5.  Salvage esophagectomy.

Authors:  Wayne L Hofstetter
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

6.  Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition.

Authors:  Kenji Sakogawa; Yoshiro Aoki; Keizo Misumi; Yoichi Hamai; Manabu Emi; Jun Hihara; Lin Shi; Kazuteru Kono; Yasunori Horikoshi; Jiying Sun; Tsuyoshi Ikura; Morihito Okada; Satoshi Tashiro
Journal:  Cancer Sci       Date:  2013-10-10       Impact factor: 6.716

7.  Inhibiting UHRF1 expression enhances radiosensitivity in human esophageal squamous cell carcinoma.

Authors:  Congrong Yang; Yadi Wang; Fuli Zhang; Guogui Sun; Chenglin Li; Shaowu Jing; Qing Liu; Yunjie Cheng
Journal:  Mol Biol Rep       Date:  2013-08-13       Impact factor: 2.316

8.  Inhibition of human positive cofactor 4 radiosensitizes human esophageal squmaous cell carcinoma cells by suppressing XLF-mediated nonhomologous end joining.

Authors:  D Qian; B Zhang; X-L Zeng; J M Le Blanc; Y-H Guo; C Xue; C Jiang; H-H Wang; T-S Zhao; M-B Meng; L-J Zhao; J-H Hao; P Wang; D Xie; B Lu; Z-Y Yuan
Journal:  Cell Death Dis       Date:  2014-10-16       Impact factor: 8.469

9.  Treatment outcomes of neoadjuvant concurrent chemoradiotherapy followed by esophagectomy for patients with esophageal cancer.

Authors:  Yong-Hyub Kim; Sang-Yun Song; Hyun-Jeong Shim; Woong-Ki Chung; Sung-Ja Ahn; Mee Sun Yoon; Jae-Uk Jeong; Ju-Young Song; Taek-Keun Nam
Journal:  Radiat Oncol J       Date:  2015-03-31

10.  Increased miRNA-22 expression sensitizes esophageal squamous cell carcinoma to irradiation.

Authors:  Xiao-chun Wang; Zhu-Bo Zhang; Yue-Ying Wang; Hong-Ying Wu; De-Guan Li; Ai-Min Meng; Fei-Yue Fan
Journal:  J Radiat Res       Date:  2012-11-27       Impact factor: 2.724

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.